Litcius/Paper detail

Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial

Michal Mego, Daniela Světlovská, Mária Rečková, De Angelis, Katarína Kaľavská, Jana Obertová, Patrik Palacka, Katarína Rejleková, Zuzana Syčová-Milá, Michal Chovanec, Jozef Mardiak

2021Investigational New Drugs18 citationsDOI

Topics & Concepts

CarboplatinGemcitabineMedicineVeliparibNeutropeniaInternal medicineClinical endpointFebrile neutropeniaPhases of clinical researchGastroenterologyRefractory (planetary science)PARP inhibitorGerm cell tumorsOncologyChemotherapySurgeryClinical trialPoly ADP ribose polymeraseCisplatinBiologyPolymeraseAstrobiologyGeneBiochemistryTesticular diseases and treatmentsPARP inhibition in cancer therapyNeuroblastoma Research and Treatments
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial | Litcius